Drug Type Monoclonal antibody |
Synonyms PF 4382923, PF-4382923, PF4382923 + [1] |
Target |
Action inhibitors |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
dry age-related macular degeneration | Phase 2 | United States | 01 Aug 2012 | |
Geographic Atrophy | Phase 2 | United States | 01 Aug 2012 |
Phase 1 | 24 | (RN6G 5 mg/kg) | tdlxxklxec = njudjaeebf aajgcgiisf (oqeebamlab, abqjrnewfa - advotgjdkk) View more | - | 12 May 2022 | ||
(RN6G 10 mg/kg) | tdlxxklxec = lezmdtoehs aajgcgiisf (oqeebamlab, mhuvomqlnz - cjrhkatacw) View more | ||||||
Phase 2 | 10 | Placebo | hnqomcbepo = oavrojpxns xwsuwfirtx (ptojhxzdai, nchzsfmtcq - asqlptxnqy) View more | - | 16 Mar 2016 | ||
Phase 1 | 57 | (RN6G 0.3 mg/kg) | ibhukinvml = kegdjeltsl hamczabvek (hznbctufxa, silvhvhtag - cgmpykfgdz) View more | - | 31 Mar 2015 | ||
(RN6G 1 mg/kg) | ibhukinvml = ovbtkmjksd hamczabvek (hznbctufxa, zoerfckdmf - pwhnvetobx) View more |